Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
about
Targeted Therapies in Adult B-Cell MalignanciesSynergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K AxisRNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase functionThe IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaDifferential effects of lenalidomide during plasma cell differentiationFront-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.Mitochondrial cereblon functions as a Lon-type protease.A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromesTranscription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.Cereblon in health and disease.The molecular mechanism of thalidomide analogs in hematologic malignancies.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Role of gut flora after bone marrow transplantation.Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesMouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitorsHigh IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.Promising therapies in multiple myeloma.Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.Knockdown of CUL4A inhibits invasion and induces apoptosis in osteosarcoma cells.Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.Lenalidomide and secondary acute lymphoblastic leukemia: a case series.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma.
P2860
Q26783195-02D6921A-CDA9-46D8-8930-1CBEE7946B1BQ33817800-56049CDC-7883-4FE1-B1DD-8EE760AFD3FCQ34974049-850E52D9-463B-4976-967F-AC8F86AB1667Q35764582-21BBF577-5AA7-493D-864E-27218D44EE07Q35784505-781AC758-F0CB-40AB-A624-2048EB3B0CC1Q35796527-B0FFA1F4-8A52-410E-86FD-21B10B118E46Q35935794-A5E0DB09-532E-4A27-A728-E1987EF6ECADQ36007765-AC399F8D-17E4-49CA-A71A-0F5D037D0D3EQ36299827-47656B56-C790-4950-9BB7-E174687081CAQ36414249-081B4FEE-3E44-4070-980C-A0B2977F1328Q37317494-011D7B75-840F-46F7-A76F-4D6017B7DDCEQ38413040-E834A22D-48FA-40E8-AEDB-7BED9B93DD5DQ38462720-44247D3B-9087-4BEB-81A6-2903A6CE53C6Q38612199-857C555B-1616-47DA-BEDA-7CECFAE5D3CAQ38709281-938719BF-8DE7-4195-9C40-D89EE48F84BAQ38758114-C05E7747-036D-489A-B6E2-8C351082BE05Q38764824-A839E499-24D3-46AF-943C-5670E31C94AFQ38852158-4E366D69-A692-46EA-9489-3E5F4C1E8618Q38876495-F91557B5-FCAA-4FEB-8948-3BEFF9E7B8DBQ38919111-B6C6D629-5BFF-4A5B-84F5-EFEA0FF74118Q39013620-4F061156-76A9-402E-9167-DB08632A011AQ39040840-FBEAABC2-2284-491B-A524-0C8955529729Q39065368-D90B2EDE-B349-452D-AD72-F4F6025B6B53Q39138108-2A7AF9E6-52F6-4396-87CA-F88D564DE69BQ39560208-B92472CE-CB33-4599-8586-6F2BD4935B59Q41115262-A30ECDD5-C2FF-41C1-A653-83DE9B61BEA4Q41593035-D4A691B3-0387-4BCA-B74A-035C5416577AQ41660363-FFC444C9-A071-414D-BC10-652B416097C8Q41770950-B1066E44-14A4-463F-BE00-7E0745C50A59Q42316993-6077FA97-03D5-4C48-A676-E562B629BDF7Q42364304-FD873FFF-44BE-4DC3-A56B-FF981AED4D38Q42399854-22A016AF-1EF2-44BD-BE7D-9EBA907FB559Q42581682-068E69FF-D082-4E03-9F4F-6091D2767C1DQ42696060-ED16327B-6D08-4480-8F6F-C5558FC47859Q42923841-B506F40B-C7C1-4101-9542-C7DFA188C131Q43742227-A29039BA-2B7F-488E-A0E9-AC5DD549B54BQ46054966-CC042930-0574-4F95-940F-A7A280A69C8AQ46408789-FD672582-AE62-4825-9CB3-7A14AD2E1E43Q46640442-873A4859-FD44-4F2F-8C7E-6BDDB223B2DBQ47141507-5E488F73-4408-42BC-A811-BAA62C466AB8
P2860
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@ast
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@en
type
label
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@ast
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@en
prefLabel
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@ast
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@en
P2093
P2860
P1433
P1476
Identification of cereblon-bin ...... ter IMiDs in multiple myeloma.
@en
P2093
A Keith Stewart
Betsy LaPlant
Chang-Xin Shi
Esteban Braggio
Jessica E Schmidt
Joseph Mikhael
K Martin Kortuem
Kristina Laumann
Laura A Bruins
Mia D Champion
P2860
P304
P356
10.1182/BLOOD-2014-02-557819
P407
P577
2014-06-09T00:00:00Z